New target to treat type 2 diabetes

Friday 15 May 2015
Image: Sohal Parvez Haque, Flickr.
Image: Sohal Parvez Haque, Flickr.

This research has significant potential for the design of new drugs to treat type 2 diabetes.”

Australian researchers have discovered a link between protein intake and improved control of blood glucose in mice, opening the way for potential new treatments for type 2 diabetes in humans.

Lead researcher Professor Stefan Broer from The Australian National University (ANU) said the findings show mice with a reduced capacity to digest and absorb protein are highly efficient at removing glucose from blood after a meal.

"This is precisely what individuals with diabetes fail to do," said Professor Broer, from the ANU Research School of Biology.

"This research has significant potential for the design of new drugs to treat type 2 diabetes."

Around one million Australians suffer from type 2 diabetes and around two million more are at risk of developing the chronic condition, which can severely impact on lifestyle and lead to high blood pressure and weight gain.

Professor Broer said the mice lacked a so-called transporter in the intestine that moves amino acids, the breakdown products of protein digestion, from the lumen of the intestine into the blood. This reduces the intake of protein and indirectly improves their efficiency at removing glucose from the blood.

The mice also have reduced levels of cholesterol and fat in the blood, which are typically elevated in obese people and can lead to the onset of diabetes.

"What makes these results so exciting is the accessibility of this target in humans. As a result it is reasonably straightforward to develop a pharmaceutical drug that blocks this transporter. If we can replicate in humans what we see in these mice we might be able to develop a new drug to treat type 2 diabetes," he said.

"We are now running a small clinical trial to test this in humans who also miss this transporter due to a rare benign genetic defect."

The research has been supported by the global healthcare company Sanofi, which produces a variety of treatment solutions for people living with diabetes.

"Without the support from Sanofi we would have not been able to do this important research in Australia," Professor Broer said.

The research has been published in the May issue of the journal Molecular Metabolism.

Related links

Journal article

Media

Updated:  22 September 2017/Responsible Officer:  Director RSB/Page Contact:  Webmaster RSB